Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients

NCT04672564 is registered in ClinicalTrials.gov with Shenyang Tonglian Group CO., Ltd as lead sponsor.

NCT NCT04672564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04672564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients
Lead sponsor
Shenyang Tonglian Group CO., Ltd
Phase
Phase 3
Overall status
Terminated
Start date
March 30, 2021
Completion date
May 9, 2022
Enrollment
93 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019